Senti Biosciences, Inc. (Senti), a biotechnology company, has filed its annual financial report for the fiscal year ended December 31, 2023. The report includes key financial metrics, business developments, and future plans. Financial Performance: The report does not provide specific financial performance figures such as revenue, operating profit, net profit, or diluted earnings per share. However, it does indicate that as of December 29, 2023, the aggregate market value of common stock held by non-affiliates was approximately $30.2 million. Additionally, as of April 16, 2024, there were 45,755,021 shares of common stock issued and outstanding. Business Development: Senti Biosciences has engaged in several strategic agreements and partnerships. These include a convertible note exchange with Bayer Healthcare LLC, a PIPE investment with certain investors, and an investor rights...Show More

Senti Biosciences, Inc. (Senti), a biotechnology company, has filed its annual financial report for the fiscal year ended December 31, 2023. The report includes key financial metrics, business developments, and future plans. Financial Performance: The report does not provide specific financial performance figures such as revenue, operating profit, net profit, or diluted earnings per share. However, it does indicate that as of December 29, 2023, the aggregate market value of common stock held by non-affiliates was approximately $30.2 million. Additionally, as of April 16, 2024, there were 45,755,021 shares of common stock issued and outstanding. Business Development: Senti Biosciences has engaged in several strategic agreements and partnerships. These include a convertible note exchange with Bayer Healthcare LLC, a PIPE investment with certain investors, and an investor rights agreement granting registration rights to certain shareholders. The company has also entered into consulting agreements with David Epstein and James Collins, and a purchase agreement with Seer, Inc. for biologics automation equipment. Future Plans: Senti Biosciences has outlined its commitment to advancing its biotechnology research and development. The company has entered into various agreements to bolster its capabilities, including a research collaboration and license agreement with Spark Therapeutics, a collaboration and option agreement with BlueRock Therapeutics, and a framework agreement with GeneFab, LLC and Valere Bio, Inc. These strategic initiatives are aimed at enhancing Senti's product offerings and market presence.